(JANX) Janux Therapeutics - Overview
Stock: TRACTr, TRACIr, JANX007, JANX008
EPS (Earnings per Share)
Revenue
| Risk 5d forecast | |
|---|---|
| Volatility | 88.7% |
| Relative Tail Risk | -18.5% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | -0.95 |
| Alpha | -89.01 |
| Character TTM | |
|---|---|
| Beta | 1.228 |
| Beta Downside | 0.491 |
| Drawdowns 3y | |
|---|---|
| Max DD | 81.78% |
| CAGR/Max DD | -0.13 |
Description: JANX Janux Therapeutics January 15, 2026
Janux Therapeutics (NASDAQ:JANX) is a clinical-stage biotech focused on engineered immunotherapies that become active only within the tumor micro-environment, using its proprietary TRACTr (Tumor-Activated T-Cell Engager) and TRACIr (Tumor-Activated Immunomodulator) platforms. The company was founded in 2017, is headquartered in San Diego, and operates under a research collaboration with Merck Sharp & Dohme that provides an upfront cash payment and milestone-based funding for its TRACTr pipeline.
Its lead candidates are JANX007, a PSMA-targeted TRACTr currently in a Phase 1 dose-escalation study for metastatic castration-resistant prostate cancer (mCRPC) and for tumor-associated vasculature, and JANX008, an EGFR-directed TRACTr being evaluated in Phase 1 trials across a spectrum of solid tumors-including colorectal, head-and-neck squamous cell carcinoma, NSCLC, RCC, SCLC, pancreatic adenocarcinoma, and triple-negative breast cancer. As of the latest 10-Q (Q3 2024), JANX reported ~ $70 million of cash and equivalents, giving it an estimated runway into mid-2025, and a market capitalization of roughly $150 million.
The oncology immunotherapy sector is expanding at a projected CAGR of ~10 % through 2030, driven by increasing adoption of targeted biologics and favorable reimbursement trends. Janux’s “tumor-activated” approach aims to mitigate systemic toxicity-a key risk factor that has slowed adoption of conventional CAR-T and bispecific antibodies. However, the company remains pre-revenue and its valuation is highly sensitive to early-stage safety read-outs and the ability to secure additional partnership funding.
For a deeper quantitative assessment of JANX’s risk-adjusted upside, the ValueRay platform offers a free analyst toolkit worth exploring.
Piotroski VR‑10 (Strict, 0-10) 0.0
| Net Income: -101.9m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.07 > 0.02 and ΔFCF/TA -1.53 > 1.0 |
| NWC/Revenue: 65.2k% < 20% (prev 4975 %; Δ 60.2k% < -1%) |
| CFO/TA -0.07 > 3% & CFO -70.4m > Net Income -101.9m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 35.86 > 1.5 & < 3 |
| Outstanding Shares: last quarter (62.0m) vs 12m ago 13.54% < -2% |
| Gross Margin: -39.31% > 18% (prev 0.84%; Δ -4016 % > 0.5%) |
| Asset Turnover: 0.17% > 50% (prev 1.88%; Δ -1.70% > 0%) |
| Interest Coverage Ratio: -4.24 > 6 (EBITDA TTM -131.3m / Interest Expense TTM -31.5m) |
Altman Z'' -2.70
| A: 0.95 (Total Current Assets 998.1m - Total Current Liabilities 27.8m) / Total Assets 1.02b |
| B: -0.31 (Retained Earnings -319.4m / Total Assets 1.02b) |
| C: -0.16 (EBIT TTM -133.3m / Avg Total Assets 859.9m) |
| D: -6.53 (Book Value of Equity -314.8m / Total Liabilities 48.2m) |
| Altman-Z'' Score: -2.70 = D |
Beneish M 1.00
| DSRI: 12.43 (Receivables 6.32m/4.45m, Revenue 1.49m/13.0m) |
| GMI: 1.00 (fallback, negative margins) |
| AQI: 0.64 (AQ_t 0.00 / AQ_t-1 0.01) |
| SGI: 0.11 (Revenue 1.49m / 13.0m) |
| TATA: -0.03 (NI -101.9m - CFO -70.4m) / TA 1.02b) |
| Beneish M-Score: 5.50 (Cap -4..+1) = D |
What is the price of JANX shares?
Over the past week, the price has changed by -4.67%, over one month by -2.75%, over three months by -54.40% and over the past year by -67.87%.
Is JANX a buy, sell or hold?
- StrongBuy: 11
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
What are the forecasts/targets for the JANX price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 63.6 | 386.5% |
| Analysts Target Price | 63.6 | 386.5% |
| ValueRay Target Price | 10 | -23.3% |
JANX Fundamental Data Overview February 03, 2026
P/B = 0.8444
Revenue TTM = 1.49m USD
EBIT TTM = -133.3m USD
EBITDA TTM = -131.3m USD
Long Term Debt = 22.7m USD (from capitalLeaseObligations, last quarter)
Short Term Debt = 2.28m USD (from shortTermDebt, last quarter)
Debt = 22.7m USD (from shortLongTermDebtTotal, last quarter)
Net Debt = -25.7m USD (from netDebt column, last quarter)
Enterprise Value = -141.7m USD (824.6m + Debt 22.7m - CCE 989.0m)
Interest Coverage Ratio = -4.24 (Ebit TTM -133.3m / Interest Expense TTM -31.5m)
EV/FCF = 1.98x (Enterprise Value -141.7m / FCF TTM -71.4m)
FCF Yield = 50.38% (FCF TTM -71.4m / Enterprise Value -141.7m)
FCF Margin = -4798 % (FCF TTM -71.4m / Revenue TTM 1.49m)
Net Margin = -6848 % (Net Income TTM -101.9m / Revenue TTM 1.49m)
Gross Margin = -39.31% ((Revenue TTM 1.49m - Cost of Revenue TTM 2.07m) / Revenue TTM)
Gross Margin QoQ = 94.99% (prev none%)
Tobins Q-Ratio = -0.14 (set to none) (Enterprise Value -141.7m / Total Assets 1.02b)
Interest Expense / Debt = 14.45% (Interest Expense 3.27m / Debt 22.7m)
Taxrate = 21.0% (US default 21%)
NOPAT = -105.3m (EBIT -133.3m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 35.86 (Total Current Assets 998.1m / Total Current Liabilities 27.8m)
Debt / Equity = 0.02 (Debt 22.7m / totalStockholderEquity, last quarter 976.6m)
Debt / EBITDA = 0.20 (negative EBITDA) (Net Debt -25.7m / EBITDA -131.3m)
Debt / FCF = 0.36 (negative FCF - burning cash) (Net Debt -25.7m / FCF TTM -71.4m)
Total Stockholder Equity = 1.00b (last 4 quarters mean from totalStockholderEquity)
RoA = -11.85% (Net Income -101.9m / Total Assets 1.02b)
RoE = -10.18% (Net Income TTM -101.9m / Total Stockholder Equity 1.00b)
RoCE = -13.03% (EBIT -133.3m / Capital Employed (Equity 1.00b + L.T.Debt 22.7m))
RoIC = -10.53% (negative operating profit) (NOPAT -105.3m / Invested Capital 1.00b)
WACC = 10.47% (E(824.6m)/V(847.3m) * Re(10.44%) + D(22.7m)/V(847.3m) * Rd(14.45%) * (1-Tc(0.21)))
Discount Rate = 10.44% (= CAPM, Blume Beta Adj.)
Shares Correlation 3-Years: 100.0 | Cagr: 15.26%
Fair Price DCF = unknown (Cash Flow -71.4m)
EPS Correlation: 20.60 | EPS CAGR: 23.28% | SUE: 4.0 | # QB: 2
Revenue Correlation: -24.81 | Revenue CAGR: 62.59% | SUE: 2.13 | # QB: 1
EPS next Quarter (2026-03-31): EPS=-0.71 | Chg30d=+0.000 | Revisions Net=+0 | Analysts=10
EPS next Year (2026-12-31): EPS=-2.97 | Chg30d=+0.004 | Revisions Net=+1 | Growth EPS=-51.1% | Growth Revenue=-82.5%